From the man who tabbed NVIDIA before it soared 6,271%
over 7 years at its peak
Wall Street’s Hottest Stock Has a Waiting List. Here’s How to Skip It.
Wealthy investors are lining up for Anthropic shares and coming up empty. Tech Visionary, Matt McCall, says you can get into a backdoor opportunity today for less than $100 a share.
Anthropic, the company behind Claude, is set to go public at a record $2 trillion valuation.
It could top SpaceX as the biggest IPO in history.
And right now, almost nobody can buy a single share.
One Wall Street broker, whose firm trades about 1,000 private stocks, told TechCrunch:
“The hardest stock to source in our marketplace is Anthropic. There’s just no sellers.”
Even Goldman Sachs is charging clients 15% to 20% of their profits just for a way in.
The Line Is Out the Door
Meanwhile, people who already own a piece of Anthropic are holding on tight.
While everyone else is stuck in line. Even wealthy investors are struggling to get shares.
And it’s all leading to the most anticipated IPO in history.
When Anthropic finally goes public, millions of regular folks will rush to buy whatever they can get.
But tech legend Matt McCall isn’t getting in line.
“Most people are going to wait for Anthropic to go public and then buy as many shares as possible,” he says. “But I think that’s a huge mistake.”
Who Is Matt McCall?
There is a short list of analysts in America who were early on the AI boom.
Matt McCall is one of them.
He’s the Head Innovation Strategist at Monument Traders Alliance and editor of The McCall Innovation Report.
Over the past two decades, McCall has written about 50 stocks that went on to peak gains of 1,000% or more. Including:
- Tesla, before it climbed as high as 3,129%
- NVIDIA, before it soared a peak 6,271% in 7 years
- AMD, which he singled out in 2009
That’s why people call him “Mr. 1,000%.”
On March 6, 2009, McCall went on FOX Business and gave away nine stocks. One was AMD, trading around two dollars. By 2026 it rose 25,000%, enough to turn a $5,000 stake into more than $1.28 million.
No Waiting List Required
McCall’s play isn’t Anthropic. It’s a stock linked to Anthropic that you can buy right now in a regular brokerage account.
No waiting list. No special broker. No fighting Wall Street for scraps.
He calls it a “Second IPO.”
It may sound too good to be true. But it has happened before.
When Rivian went public in 2021, Ford owned a 12% stake. In the six months around Rivian’s IPO, Ford shares roughly doubled.
Yahoo quietly built a huge stake in Alibaba. In the two years around Alibaba’s IPO, Yahoo shares could have tripled your money.
It happened again shortly after EchoStar acquired $8.5 billion in SpaceX shares. In the months leading up to the SpaceX IPO, its shares soared 600%.
Now it’s happening again!
Anthropic’s “Silent Partner”
Years before the IPO frenzy, a much smaller firm took a $100 million stake in Anthropic. It beat Apple, NVIDIA, Amazon and Google to the punch.
Today, the entire company is valued at less than $15 billion. That’s 100x smaller than Anthropic.
McCall believes its early stake could cause it to double or triple in the years ahead.
And you can buy it for less than $100 a share.
We sat McCall down in front of our cameras to get the whole story. He even gave away the name and ticker.
For the time being, you can watch it free.
|
“If history repeats… investors could double or triple their money in the years ahead.” – Matt McCall
CYTK’s FDA Deadline Is Saturday. The Stock Has Already Priced In Failure.
Cytokinetics stock dropped about 13% on November 5, the morning after a quarter where it beat both revenue and earnings estimates. The company delivered earnings and revenue surprises versus consensus estimates for the quarter ended September 30, 2026. That reaction is worth examining carefully, because the selloff did not come from the numbers. It came from what traders are pricing for Saturday.
What the Earnings Actually Showed
Total revenues for the third quarter of 2026 were $47.6 million, compared to $1.9 million for the same period in 2025, including $44.5 million in MYQORZO net product revenue, with $43.1 million from the U.S. and $1.4 million from Europe reflecting product revenue in Germany. That represented a 76% sequential increase in MYQORZO net product revenue. The company ended Q3 with approximately $1.6 billion in cash, cash equivalents and investments. On its own, none of this reads as a catalyst for a double-digit selloff.
The commercial picture is more instructive than the revenue line. Of approximately 120,000 eligible oHCM patients in the U.S., management has said only about 28,000 are treated with a cardiac myosin inhibitor today. Management has also said MYQORZO reached roughly 45% new-to-brand exit share in the cardiac myosin inhibitor category, with higher share among high-volume prescribers. These are not metrics that describe a drug struggling to gain traction.
The MAPLE-HCM Decision and What It Changes
The November 14 PDUFA date covers the MAPLE-HCM supplemental NDA. An FDA decision on this data could further differentiate MYQORZO’s clinical profile against standard beta blockers. The underlying trial data is clear. The primary results of MAPLE-HCM demonstrated superiority of aficamten to metoprolol on pVO2, with a least-squares mean treatment difference of +2.3 mL/kg/min (p<0.001). Significantly greater improvements in NYHA class, KCCQ-CSS, left ventricular outflow tract gradient, and NT-proBNP level were also reported for aficamten versus metoprolol.
An expanded label that positions aficamten as a monotherapy alternative to metoprolol could meaningfully shift prescribing behavior. Community cardiologists now account for a majority of the MYQORZO prescriber base, indicating penetration beyond academic centers.
Analyst Positioning and the Gap
As of November 11, 2026, published analyst aggregates show a Street mean price target around $109, with highs in the $140 area. Against a stock trading near $63, that gap is not noise.
The PDUFA-driven gap between price and analyst targets is not unique to CYTK. Vertex is carrying a similar binary FDA date that the Street is pricing into a stock already well above its commercial base.
Scenario Modeling
Bull Case: FDA approves the MAPLE-HCM label expansion Saturday. CYTK recaptures territory toward its 52-week high of $88.31. Prescriber education around monotherapy accelerates penetration into the remaining untreated eligible patients. Shares test $80 near-term. Management has also said nHCM is a market similar in scale to oHCM, and CYTK would be first and only if approved there.
Base Case: FDA approves with a narrower label than sought, or issues a complete response letter requiring additional data. Stock stabilizes near current levels. The commercial MYQORZO trajectory, plus the planned Q4 nHCM sNDA submission, keeps downside contained by fundamentals.
Bear Case: Outright rejection combined with a broader biotech risk-off move. CYTK revisits the low end of its recent range. Quarterly SG&A of $113.1 million as commercial launch costs continue rising means the cash burn clock accelerates if the top-line growth rate stalls.
Binary regulatory events carry asymmetric downside when the bear case combines rejection with sector-wide risk-off. Vir Biotechnology’s Phase 3 readout shows how a strong efficacy result can still leave traders exposed to label-scope uncertainty and first-mover competition.
Trading Framework
The 52-week range runs from $47.22 to $88.31. Post-earnings, the stock settled near $63, more than 28% below its high. Volume on the selloff day ran to roughly twice the average. For traders sizing positions ahead of a binary regulatory event, the risk-reward arithmetic depends entirely on position size relative to the overnight gap risk the PDUFA date creates. Options pricing reflects elevated implied volatility into Saturday. Neither the upside case nor the downside case is remote, which is precisely what makes disciplined sizing the only variable a trader controls.
The commercial data supports the bull thesis. The FDA has the trial data to support approval. What the market does not know, and cannot know before Saturday, is how the agency weighs the label scope. Preparation, not prediction, is the trade.
